59357-U
Discovery® Cyano (5 µm) HPLC Columns
L × I.D. 25 cm × 4.6 mm, HPLC Column
別名:
TM =［「Discovery」］HPLC クロマトグラフィー
ログインで組織・契約価格をご覧ください。
サイズを選択してください
表示を変更する
この商品について
UNSPSC Code:
41115700
eCl@ss:
32110501
NACRES:
SB.52
L × i.d.:
25 cm × 4.6 mm
Particle size:
5 μm
Matrix active group:
cyano phase
Pore size:
180 Å
Matrix:
silica gel, high purity, spherical base material, fully porous particle
製品名
Discovery®Cyano HPLCカラム, 5 μm particle size, L × I.D. 25 cm × 4.6 mm
material
stainless steel column
Quality Level
agency
suitable for USP L10
product line
Discovery®
feature
endcapped
manufacturer/tradename
Discovery®
packaging
1 ea of
extent of labeling
4.5% Carbon loading
parameter
≤70 °C temp. range, 400 bar pressure (5801 psi)
technique(s)
HPLC: suitable, LC/MS: suitable
L × I.D.
25 cm × 4.6 mm
surface area
200 m2/g
surface coverage
3.5 μmol/m2
impurities
<10 ppm metals
matrix
silica gel, high purity, spherical base material, fully porous particle
matrix active group
cyano phase
particle size
5 μm
pore size
180 Å
operating pH range
2-8
application(s)
food and beverages
separation technique
hydrophilic interaction (HILIC), normal phase, reversed phase
Features and Benefits
- 疎水性分析対象物の迅速な溶出に要する疎水性の低さ
- 優れたピ-ク形状および強塩基性分析対象物の保持
- 極性分析対象物の保持
- 独自の選択性
- C18カラムよりも顕著に低い保持(低濃度の有機系移動相が必要)
- 安定で低ブリ-ドのLC-MS分離
- 水系有機溶媒の濃度が高い移動相で使用可能
Legal Information
Discovery is a registered trademark of Merck KGaA, Darmstadt, Germany
Still not finding the right product?
Explore all of our products under Discovery®Cyano HPLCカラム
E F Nemeth et al.
The Journal of pharmacology and experimental therapeutics, 299(1), 323-331 (2001-09-19)
Despite the discovery of many ions and molecules that activate the Ca2+ receptor, there are no known ligands that block this receptor. Reported here are the pharmacodynamic properties of a small molecule, NPS 2143, which acts as an antagonist at
S L Able et al.
British journal of pharmacology, 162(2), 405-414 (2010-09-16)
The P2X7 receptor is implicated in inflammation and pain and is therefore a potential target for therapeutic intervention. Here, the development of a native tissue radioligand binding, localization and ex vivo occupancy assay for centrally penetrant P2X7 receptor antagonists is
Thomas J Woltering et al.
Bioorganic & medicinal chemistry letters, 18(3), 1091-1095 (2007-12-22)
A series of 1,3-dihydro-benzo[b][1,4]diazepin-2-one derivatives was evaluated as non-competitive mGluR2/3 antagonists. Replacement of a cyano group by a five-membered heterocycle produced compounds inhibiting the binding of [(3)H]-LY354740 to rat mGluR2 with low nanomolar affinity and consistent functional effect at both